AG
STRO icon

Advisor Group’s Sutro Biopharma STRO Stock Holding History

Advisor Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2K Hold
20
– – ﹤0.01% 5023
2019
Q3 		$2K Hold
20
– – ﹤0.01% 5003
2019
Q2 		$2K Hold
20
– – ﹤0.01% 5009
2019
Q1 		$2K Hold
20
– – ﹤0.01% 4977
2018
Q4 		$2K Buy
+20
New +$2.41K ﹤0.01% 4849

Other funds holding STRO

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group's STRO Position: Q4 2019 in Review

Advisor Group held its Sutro Biopharma (STRO) position steady in Q4 2019 at 20 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #5023.

Advisor Group first reported a position in STRO in Q4 2018 and has held it in 5 quarters since. 64 funds tracked by Wall St. Rank hold STRO as of Q4 2019.

  • Advisor Group held 20 shares of Sutro Biopharma worth $2K as of Q4 2019.
  • Advisor Group left its Sutro Biopharma share count unchanged in Q4 2019.
  • Sutro Biopharma made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5023 holding.
  • Advisor Group first reported a position in Sutro Biopharma in Q4 2018 and has held it in 5 quarters since.
  • 64 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.